128 related articles for article (PubMed ID: 9502556)
1. Neoral induction in pediatric renal transplantation.
Bunchman TE; Parekh RS; Flynn JT; Smoyer WE; Kershaw DB; Valentini RP; Pontillo BJ; Sandvordenker J; Brown C; Sedman AB
Pediatr Nephrol; 1998 Jan; 12(1):2-5. PubMed ID: 9502556
[TBL] [Abstract][Full Text] [Related]
2. Safety and tolerability of a new oral formulation of cyclosporin A, Sandimmun Neoral, in renal transplant patients.
Taesch S; Niese D
Transpl Int; 1994; 7 Suppl 1():S263-6. PubMed ID: 11271220
[TBL] [Abstract][Full Text] [Related]
3. Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation. International Sandimmun Neoral Study Group.
Keown P; Niese D
Kidney Int; 1998 Sep; 54(3):938-44. PubMed ID: 9734620
[TBL] [Abstract][Full Text] [Related]
4. Randomized trial of cyclosporine microemulsion (neoral) versus conventional cyclosporine in liver transplantation: MILTON study. Multicentre International Study in Liver Transplantation of Neoral.
Otto MG; Mayer AD; Clavien PA; Cavallari A; Gunawardena KA; Mueller EA
Transplantation; 1998 Dec; 66(12):1632-40. PubMed ID: 9884251
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of cyclosporine in pediatric long-term liver transplant recipients converted from Sandimmun to Neoral.
Melter M; Rodeck B; Kardorff R; Hoyer PF; Brodehl J
Transpl Int; 1997; 10(6):419-25. PubMed ID: 9428114
[TBL] [Abstract][Full Text] [Related]
6. Randomized, trough blood cyclosporine concentration-controlled trial to compare the pharmacodynamics of Sandimmune and Neoral in de novo lung transplant recipients.
Trull A; Steel L; Sharples L; Stewart S; Parameshwar J; McNeil K; Wallwork J
Ther Drug Monit; 1999 Feb; 21(1):17-26. PubMed ID: 10051050
[TBL] [Abstract][Full Text] [Related]
7. [Effect of diltiazem on concentration of cyclosporin metabolites in Sandimmune and Neoral treated kidney transplant patients].
Sperschneider H; Wagner C; Korn A; Christians U
Med Klin (Munich); 1997 Oct; 92(10):589-96. PubMed ID: 9446006
[TBL] [Abstract][Full Text] [Related]
8. Neoral vs Sandimmun: interim results of a randomized trial of efficacy and safety in preventing acute rejection in new renal transplant recipients. The U. K. Neoral Study Group.
Lodge JP; Pollard SG
Transplant Proc; 1997; 29(1-2):272-3. PubMed ID: 9122991
[No Abstract] [Full Text] [Related]
9. Safety and tolerability of Sandimmun Neoral vs Sandimmun in de novo renal transplant patients after 24 months' treatment. German Neoral Study Group.
Buchholz B; Korn A
Transplant Proc; 1996 Aug; 28(4):2187-8. PubMed ID: 8769195
[No Abstract] [Full Text] [Related]
10. Long-term experience with Sandimmun Neoral: results in de novo and stable renal transplant patients after 24-month treatment. The German Neoral Study Group.
Korn A; Färber L; Maibücher A; Buchholz B; Offermann G
Transplant Proc; 1997 Nov; 29(7):2945-7. PubMed ID: 9365623
[No Abstract] [Full Text] [Related]
11. Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation.
Canadian Neoral Renal Transplantation Study Group
Transplantation; 2001 Sep; 72(6):1024-32. PubMed ID: 11579295
[TBL] [Abstract][Full Text] [Related]
12. [Passage from sandimmun to neoral in kidney transplantation in children].
Broyer M; Maisin A; Guest G; Baudouin V; Charbit M; Reigneau O; Loirat C
Arch Pediatr; 1999 Oct; 6(10):1066-9. PubMed ID: 10544781
[TBL] [Abstract][Full Text] [Related]
13. Conversion from conventional Sandimmun to Neoral therapy in stable renal transplant recipients.
Løkkegaard H; Asmundsson P; Clausen P; Dieperink H; Hansen JM; Heaf J; Jensen SB; Kornerup HJ; Madsen S; Pedersen EB; Poulsen JV; Rasmussen K
Transplant Proc; 1996 Aug; 28(4):2199-201. PubMed ID: 8769199
[No Abstract] [Full Text] [Related]
14. Randomized, double-blind, one-year study of the safety and tolerability of cyclosporine microemulsion compared with conventional cyclosporine in renal transplant patients. International Sandimmun Neoral Study Group.
Frei UA; Neumayer HH; Buchholz B; Niese D; Mueller EA
Transplantation; 1998 Jun; 65(11):1455-60. PubMed ID: 9645802
[TBL] [Abstract][Full Text] [Related]
15. Comparison of efficacy, safety, and tolerability of Neoral vs Sandimmun in de novo renal transplant patients over 24 months' treatment.
Abendroth D; Buchholz B; Land W; May G; Wiesel M; Färber L; Korn A; Maibücher A
Transplant Proc; 1997; 29(1-2):275-6. PubMed ID: 9122993
[No Abstract] [Full Text] [Related]
16. Comparison of Neoral and Sandimmun cyclosporin A pharmacokinetic profiles in young renal transplant recipients.
Kabasakul SC; Clarke M; Kane H; Karsten J; Clark G
Pediatr Nephrol; 1997 Jun; 11(3):318-21. PubMed ID: 9203180
[TBL] [Abstract][Full Text] [Related]
17. Comparison of microemulsion and conventional formulations of cyclosporine A in preventing acute rejection in de novo kidney transplant patients. The U.K. Neoral Renal Study Group.
Pollard SG; Lear PA; Ready AR; Moore RH; Johnson RW
Transplantation; 1999 Nov; 68(9):1325-31. PubMed ID: 10573071
[TBL] [Abstract][Full Text] [Related]
18. Experience with clinical use of Sandimmun Neoral in renal transplant patients.
Min ZL; Zhao M; Zhu YH; Qi J; Wang LM; Wang YW
Transplant Proc; 1996 Jun; 28(3):1356-7. PubMed ID: 8658692
[No Abstract] [Full Text] [Related]
19. Advantages of Neoral conversion in renal transplant patients.
Vennarecci G; Pisani F; Tisone G; Buonomo O; Famulari A; Casciani CU
Minerva Urol Nefrol; 1998 Jun; 50(2):161-4. PubMed ID: 9707972
[TBL] [Abstract][Full Text] [Related]
20. Neoral compared to Sandimmune is associated with a decrease in histologic severity of rejection in patients undergoing primary liver transplantation.
Graziadei IW; Wiesner RH; Marotta PJ; Porayko MK; Dahlke LJ; Wilson SM; Steers JL; Krom RA
Transplantation; 1997 Sep; 64(5):726-31. PubMed ID: 9311710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
